Received: from nobody by stodi.digitalkingdom.org with local (Exim 4.76) (envelope-from ) id 1UUkyL-0000zc-HD for lojban-newreal@lojban.org; Tue, 23 Apr 2013 14:41:57 -0700 Received: from innorn.com ([154.57.72.58]:47804) by stodi.digitalkingdom.org with esmtp (Exim 4.76) (envelope-from ) id 1UUkyF-0000yw-3T for lojban@lojban.org; Tue, 23 Apr 2013 14:41:56 -0700 DKIM-Signature: v=1; a=rsa-sha1; c=relaxed/relaxed; s=pl1; d=innorn.com; h=To:Subject:Message-ID:Date:From:Reply-To:MIME-Version:List-Unsubscribe:Content-Type:Content-Transfer-Encoding; i=jakob@innorn.com; bh=gU6/IKbxeA4RIh6NNtT3FVwSZNE=; b=h7YC334QUWIOTMnB621FZO5K+qkBr226Fs5gFKW298FhOINCffNOTYEJaUbN9lHq79hzQcmEcVhC zdZDgUzTIxW7IRdPvrUTHZ8GB1gorrZ06egIatG3Yx0dY6HfEhLP/LccRavrGKH+Q882vLM3Xd0o HZ0YkT+oXPA6StFCAT8= DomainKey-Signature: a=rsa-sha1; c=nofws; q=dns; s=pl1; d=innorn.com; b=TtiKEZs2q2305/akfnxPMTTdhnB5JNaHFDY4HyaQU7OqtognL+G5GcAH2aMrm0RJgEpXIgBuoPnV /p9Qxk6A6uCvgzXMFvvDb1Bwxtzie/QgRFcJeblSLsXRNGtWvCwJy47570p4MQ52Stbn4zWK654V rby7q3U2FZXwJ3nKCjQ=; To: lojban@lojban.org Subject: =?UTF-8?B?TnV2aWxleCwgSW5jLuKAmXMgRGlhYmV0ZXMgUmVzZWFyY2ggTWlnaHQgTGVhZCB0byBhIFR5cGUgb2Yg4oCcQXJ0aWZpY2lhbCBQYW5jcmVhc+KAnSBhbmQgRWxpbWluYXRlIFJlZ3VsYXIgSW5zdWxpbiBSZXF1aXJlbWVudHM=?= Message-ID: <1f9fbdceebcd25e69b6842417620de0f@innorn.com> Date: Tue, 23 Apr 2013 16:06:48 -0500 From: "Newsletter" Reply-To: jakob@innorn.com MIME-Version: 1.0 X-Mailer-LID: 72,99 List-Unsubscribe: X-Mailer-RecptId: 29646973 X-Mailer-SID: 549 X-Mailer-Sent-By: 1 Content-Type: multipart/alternative; charset="UTF-8"; boundary="b1_425228146734e49755c0adb9421b1975" Content-Transfer-Encoding: 8bit X-Spam-Score: -0.7 (/) X-Spam_score: -0.7 X-Spam_score_int: -6 X-Spam_bar: / --b1_425228146734e49755c0adb9421b1975 Content-Type: text/plain; format=flowed; charset="UTF-8" Content-Transfer-Encoding: 8bit Nuvilex, Inc.’s Diabetes Studies Might Lead to a Type of “Artificial Pancreas” and Erradicate Regular Insulin Requirements When investors consider biotechnology and pharma companies as an investment option, 3 regions of research are prominent as the most favorable for future revenues. The big 3 are cancer, heart disease and diabetes research which can ultimately direct to related clinical trials. Well, Nuvilex, Inc. (OTCQB: NVLX) is currently involved in 2 of the 3 – cancer and diabetes. Get more research on what industry leaders has to say about Nuvilex and Diabetes. Read on http://innorn.com/link.php?M=29646973&N=549&L=11&F=T The usage of research materials distributed by the author is done at your own risk. You are urged to do your own research and due diligence before making any investment decision with respect to the secu rity discussed herein. The author has not been compensated by any entity in connection with the distribution of these materials. You should assume that as of the date of this report or letter, the author, (possibly along with or through our owners, affiliates, employees and/or consultants”) (communally referred to as the author) has a position in all company shares (and/or options of the shares) covered herein that is consistent with the position set forth in our report. In connection with NVLX, the author has taken a long position. Following the disbursement of any report or letter, the author intends to continue engaging in trnsactns in the security covered herein, and we may be long, short, and/or neutral at any time hereafter regardless of our initial position and we preserve the right to procure or trade all or part of our position at any time without notice. This practice could end in our trading securities at any time before, during, and/or after the disbursement of this report. Full disclaimer: http://innorn.com/link.php?M=29646973&N=549&L=8&F=T Unsubscribe http://innorn.com/unsubscribe.php?M=29646973&C=dfde2e12c02c5d5f2da491323a930c2f&L=72&N=549 One hundred N 18th St., Suite 300, Philadelphia, PA 19103 USA --b1_425228146734e49755c0adb9421b1975 Content-Type: text/html; charset="UTF-8" Content-Transfer-Encoding: 8bit
Nuvilex, Inc.’s Diabetes Research Might Lead to a Type of “Artificial Pancreas” and Erradicate Regular Insulin Requirements
When investors look into biotechnology and pharma organizations as an investment option, three areas of research stick out as the most favorable for future earnings. The big 3 are cancer, heart disease and diabetes research that can in time head to related clinical trials. Well, Nuvilex, Inc. (OTCQB: NVLX) is currently involved in 2 of the 3 – cancer and diabetes.

Get more research on what others has to say about Nuvilex and Diabetes. Read on


The usage of research materials distributed by the author is done at your own risk.  You are encouraged to do your own research and due diligence before making any investment decision in regards to the secu rity discussed herein. The author has not been compensated by any entity in connection with the distribution of these materials. You should presume that as of the date of this report or letter, the author, (possibly along with or through our owners, affiliates, employees and/or consultants”) (communally referred to as the author) has a position in all company shares (and/or options of the shares) covered herein that is consistent with the position set forth in our report. In connection with NVLX, the author has taken a long position. Following the disbursement of any report or letter, the author plans to continue engaging in trnsactns in the security covered herein, and we may be long, short, and/or neutral at any time hereafter regardless of our initial position and we preserve the right to procure or trade all or part of our position at any time without notice.  This practice could end in our trading securities at any time before, during, and/or after the distribution of this report. Full disclaimer


Unsubscribe
100 N 18th ST, Ste. 300, Philadelphia, PA 19103  United States
--b1_425228146734e49755c0adb9421b1975--